Identification of SARS-CoV-2-specific immune alterations in acutely ill patients

Autor: Yves Carpentier Solorio, Antoine P. Fournier, Catherine Larochelle, Hélène Jamann, Olivier Tastet, Ana Carmena Moratalla, Camille Grasmuck, Elizabeth Gowing, Madeleine Durand, Negar Farzam-Kia, Marc Charabati, Daniel Kaufmann, Victoria Hannah Mamane, Nicolas Chomont, Florent Lemaître, Jean-François Cailhier, Alexandre Prat, Rose-Marie Rébillard, Abdelali Filali-Mouhim, Audrey Daigneault, Nathalie Brassard, Karine Thai, Lyne Bourbonnière, Michaël Chassé, Renaud Balthazard, Andrés Finzi, Nathalie Arbour
Rok vydání: 2020
Předmět:
DOI: 10.1101/2020.12.21.20248642
Popis: Dysregulated immune profiles have been described in symptomatic SARS-CoV-2-infected patients. Whether the reported immune alterations are specific to SARS-CoV-2 infection or also triggered by other acute illnesses remains unclear. We performed flow cytometry analysis on fresh peripheral blood from a consecutive cohort of i) patients hospitalized with acute SARS-CoV-2 infection; ii) patients of comparable age/sex hospitalized for other acute disease (SARS-CoV-2 negative); and iii) healthy controls. Using both data-driven and hypothesis-driven analyses, we found several dysregulations in immune cell subsets (e.g. decreased proportion of T cells) that are similarly associated with acute SARS-CoV-2 infection and non-COVID-19 related acute illnesses. In contrast, we identified specific differences in myeloid and lymphocyte subsets that are associated with SARS-CoV-2 status (e.g. elevated proportion of ICAM-1+mature/activated neutrophils, ALCAM+monocytes, and CD38+CD8+T cells). A subset of SARS-CoV-2-specific immune alterations correlated with disease severity, disease outcome at 30 days and mortality. Our data provides novel understanding of the immune dysregulation that are specifically associated with SARS-CoV-2 infection among acute care hospitalized patients. Our study lays the foundation for the development of specific biomarkers to stratify SARS-CoV-2+patients at risk of unfavorable outcome and uncover novel candidate molecules to investigate from a therapeutic perspective.
Databáze: OpenAIRE